靶向治疗与颅内转移性疾病的相关性评估
这项回顾性队列研究纳入加拿大安大略省2005年4月至2018年1月诊断为颅内转移性疾病(IMD)的乳腺癌、肺癌或黑色素瘤患者,评估靶向治疗与IMD患者生存的相关性。结果显示,IMD后靶向治疗与ERBB2阳性乳腺癌、EGFR阳性肺癌和BRAF阳性黑色素瘤患者的总生存期延长相关;IMD的存在与ERBB2阳性乳腺癌和EGFR阳性肺癌患者更短的总生存期相关,但与BRAF阳性黑色素瘤无关。
要点
- IMD后靶向治疗与ERBB2阳性乳腺癌、EGFR阳性肺癌和BRAF阳性黑色素瘤患者总生存期延长相关。
- IMD的存在与ERBB2阳性乳腺癌和EGFR阳性肺癌患者更短的总生存期相关。
- IMD的存在与BRAF阳性黑色素瘤患者的总生存期无关。
核心结论
- 在真实世界中,IMD后使用靶向治疗与ERBB2阳性乳腺癌、EGFR阳性肺癌和BRAF阳性黑色素瘤患者的总生存期延长相关。
- IMD的存在与ERBB2阳性乳腺癌和EGFR阳性肺癌患者更短的总生存期相关,但与BRAF阳性黑色素瘤无关。
- 将IMD患者纳入临床试验并使用评估颅内结局的终点对确定靶向治疗在IMD中的作用至关重要。
研究设计与样本
- 回顾性队列研究纳入加拿大安大略省2005年4月至2018年1月诊断为IMD且原发诊断为乳腺癌、肺癌或黑色素瘤的患者,以及按原发疾病匹配的无IMD对照患者。
- 暴露因素为EGFR靶向治疗、ERBB2(HER2)靶向治疗或BRAF靶向治疗,或IMD状态。
- 采用Kaplan-Meier和多变量Cox回归分析比较按原发疾病划分并按靶向治疗接受情况或IMD状态分层的亚队列间的总生存期。
主要发现
- 与未接受IMD后靶向治疗者相比,IMD后靶向治疗与ERBB2阳性乳腺癌患者总生存期延长相关(HR 0.41;95%CI 0.33-0.50)。
- 与未接受IMD后靶向治疗者相比,IMD后靶向治疗与EGFR阳性肺癌患者总生存期延长相关(HR 0.28;95%CI 0.23-0.34)。
- 与未接受IMD后靶向治疗者相比,IMD后靶向治疗与BRAF阳性黑色素瘤患者总生存期延长相关(HR 0.20;95%CI 0.14-0.29)。
- 与无IMD者相比,IMD的存在与转移性ERBB2阳性乳腺癌患者更短的总生存期相关(HR 1.80;95%CI 1.56-2.08)。
- 与无IMD者相比,IMD的存在与转移性EGFR阳性肺癌患者更短的总生存期相关(HR 1.22;95%CI 1.08-1.39),但与转移性BRAF阳性黑色素瘤患者的总生存期无关(HR 1.11;95%CI 0.77-1.61)。
临床怎么用
- 在临床实践中,对于ERBB2阳性乳腺癌、EGFR阳性肺癌和BRAF阳性黑色素瘤的IMD患者,可考虑使用相应靶向治疗以延长总生存期。
- 应关注IMD对ERBB2阳性乳腺癌和EGFR阳性肺癌患者生存的不利影响,并加强颅内疾病管理。
局限性
- 本研究为回顾性队列研究,可能存在未测量的混杂因素。
- 临床试验通常排除IMD患者且缺乏报告颅内结局的终点,导致真实世界证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Targeted therapies have been hypothesized to prolong survival in the treatment of patients with intracranial metastatic disease (IMD) but, paradoxically, increase IMD incidence by improving systemic disease control and prolonging survival from the primary tumor. The real-world benefits of targeted therapy in treating patients with IMD are unclear, as clinical trials have excluded patients with IMD and lacked end points that report intracranial outcomes. OBJECTIVE: To assess the association of targeted therapy and IMD with patient survival. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included all patients in Ontario, Canada, who received a diagnosis of IMD from April 2005 to January 2018 with primary diagnoses of breast cancer, lung or bronchus cancer, or melanoma and control patients who were matched by primary disease without IMD. The data were analyzed between March and October 2020. EXPOSURES: EGFR-, ERBB2 (HER2-), or BRAF-targeted therapy or IMD status. MAIN OUTCOMES AND MEASURES: Kaplan-Meier and multivariable Cox regression analyses were performed to compare overall survival (OS) between patient subcohorts divided by primary disease and stratified by targeted therapy receipt or IMD status. RESULTS: In this cohort of 26 676 patients with IMD and breast cancer, lung and bronchus cancer, or melanoma, 57% of patients were women, and the median age at IMD diagnosis was 64 years (interquartile range, 56-72 years). Post-IMD targeted therapy was associated with prolonged OS in patients with ERBB2-positive breast cancer (hazard ratio [HR], 0.41; 95% CI, 0.33-0.50), EGFR-positive lung cancer (HR, 0.28; 95% CI, 0.23-0.34), and BRAF-positive melanoma (HR, 0.20; 95% CI, 0.14-0.29) compared with those who did not receive post-IMD targeted therapy. The presence of IMD was associated with shorter OS in patients with metastatic ERBB2-positive breast cancer (HR, 1.80; 95% CI, 1.56-2.08) and metastatic EGFR-positive lung cancer (HR, 1.22; 95% CI, 1.08-1.39) but not metastatic BRAF-positive melanoma (HR, 1.11; 95% CI, 0.77-1.61) compared with those without IMD. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest an association between real-world use of targeted therapies and prolonged OS in patients with IMD in the setting of ERBB2-positive breast cancer, EGFR-positive lung cancer, and BRAF-positive melanoma. Including patients with IMD in clinical trials and using end points that interrogate IMD will be critical to determine the role of targeted therapies in treating patients with IMD.
引用
- Erickson AW, Habbous S, Wright F, et al. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. JAMA Oncol. 2021. PMID: 34081080. doi:10.1001/jamaoncol.2021.1600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。